Skip to main content
Premium Trial:

Request an Annual Quote

Seven Bridges Raises $15M in First Closing of Series C

NEW YORK – Seven Bridges Genomics said Tuesday that it has raised $15 million from a new investor in the first closing of a planned $30 million Series C round of venture capital. The Boston-based multiomic bioinformatics company did not disclose the name of the investor but said it was a new shareholder that works in life sciences.

Seven Bridges said that the second half of the round is expected to close before the end of the second quarter.

"Multiomics tools are fast becoming ubiquitous drivers of scientific innovation," Seven Bridges CEO William Moss said in a statement. "This new investment … will help us continue to innovate and scale our organization to serve our customers’ rapidly evolving needs to utilize multiomics data in their research."

The firm has brought in about $113 million in venture capital since its inception in 2009. Seven Bridges raised $3 million in a seed round in 2014, $45 million in a Series A round in 2016, and $50 million in a Series B round in 2018.

The Scan

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.

Neurological Outcomes Linked to Innate Immune Features After Cardiac Arrest

Researchers reporting in Med dig into immune features found a few hours after cardiac arrest that correspond with neurological outcomes.

Mouse Study Finds Circadian Rhythm-Related Gene Expression Changes Linked to Sleep Apnea

A paper in PLOS Biology reveals tissue-specific circadian rhythm and gene expression patterns in an intermittent hypoxia-based mouse model of obstructive sleep apnea.

Polygenic Risk Score to Predict Preeclampsia, Gestational Hypertension in Pregnant Women

Researchers in Nature Medicine provide new mechanistic insights into the development of hypertensive disorders of pregnancy, which may help develop therapeutics.